# The association between organophosphate pesticide residue exposure and non-alcoholic fatty liver disease: A systematic review

**Authors:** Bahare Mohamadi, Mohammadreza Tolou Ostadan, Samira Shokri, Alireza Bakhtiyari, Rokhsana Rasooli, Parisa Sadighara, Saeed Aghebat-Bekheir

PMC · DOI: 10.1016/j.toxrep.2026.102216 · Toxicology Reports · 2026-02-03

## TL;DR

This review explores the link between organophosphate pesticide exposure and non-alcoholic fatty liver disease, highlighting key findings and gaps in understanding.

## Contribution

The paper systematically reviews evidence connecting organophosphate pesticide residues to NAFLD and identifies key metabolites and research gaps.

## Key findings

- There is a link between exposure to organophosphate pesticides and non-alcoholic fatty liver disease.
- Demographic characteristics influence the severity of liver complications caused by organophosphate pesticides.
- Diet can be a strategy to reduce NAFLD caused by organophosphate pesticide exposure.

## Abstract

Non-alcoholic fatty liver disease (NAFLD) is a chronic disease that has had a significant prevalence in recent decades. Various factors contribute to the disease, with diet being one of the most important. In recent decades, several studies have reported a correlation between agricultural pesticide residues and NAFLD. This systematic review aimed to discuss scientific findings and analyze evidence of the association between organophosphate pesticide residues and NAFLD. To achieve this, relevant keywords were identified, and a search protocol was established in databases over the past decade to facilitate article retrieval. Finally, a total of 314 articles were identified through the search, of which 21 met the inclusion criteria and were selected for this review. This review identified a diverse range of OPs and their metabolites concerning NAFLD. Glyphosate and its formulations (such as Roundup) were the most studied OPs. The key OPE metabolites most frequently studied were BDCIPP, BCIPHIPP, DPHP, and BCEP. In addition, pesticides such as triphenyl phosphate (TPHP), trichlorofon, tris(1-chloro-2-propyl) phosphate (TCPP), tris(2-chloroethyl) phosphate (TCEP), and tri-ortho-cresyl phosphate (TOCP) were also investigated. The primary method for assessing OPs exposure involved measuring urinary metabolites. We discuss the evidence for the correlation between exposure to OPs and NAFLD, as well as the factors that influence it.

•There is a link between exposure to OPs and NAFLD.•Demographic characteristics influence the severity of liver complications caused by OPs.•The reference dose of OPs leading to NAFLD remains a knowledge gap.•Diet can be a strategy to reduce NAFLD caused by OPs.•Identifying the metabolic pathways of OPs is essential for defining prevention strategies.

There is a link between exposure to OPs and NAFLD.

Demographic characteristics influence the severity of liver complications caused by OPs.

The reference dose of OPs leading to NAFLD remains a knowledge gap.

Diet can be a strategy to reduce NAFLD caused by OPs.

Identifying the metabolic pathways of OPs is essential for defining prevention strategies.

## Linked entities

- **Chemicals:** glyphosate (PubChem CID 3496), Roundup (PubChem CID 38078), BDCIPP (PubChem CID 188119), BCIPHIPP (PubChem CID 132967160), BCEP (PubChem CID 76438), trichlorofon (PubChem CID 5853)
- **Diseases:** non-alcoholic fatty liver disease (MONDO:0013209), NAFLD (MONDO:0013209)

## Full-text entities

- **Genes:** PON1 (paraoxonase 1) [NCBI Gene 5444] {aka ESA, MVCD5, PON}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, ACHE (acetylcholinesterase (Yt blood group)) [NCBI Gene 43] {aka ACEE, ARACHE, N-ACHE, YT}, HSPA5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 3309] {aka BIP, GRP78, HEL-S-89n}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, FASN (fatty acid synthase) [NCBI Gene 2194] {aka FAS, OA-519, SDR27X1}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, CAT (catalase) [NCBI Gene 847], SERPINA1 (serpin family A member 1) [NCBI Gene 5265] {aka A1A, A1AT, AAT, PI, PI1, PRO2275}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, H6PD (hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase) [NCBI Gene 9563] {aka CORTRD1, G6PDH, GDH, H6PDH}, GGTLC4P (gamma-glutamyltransferase light chain 4 pseudogene) [NCBI Gene 729838] {aka GGT}, ATHS (atherosclerosis susceptibility (lipoprotein associated)) [NCBI Gene 470] {aka ALP}, DDIT3 (DNA damage inducible transcript 3) [NCBI Gene 1649] {aka AltDDIT3, C/EBPzeta, CEBPZ, CHOP, CHOP-10, CHOP10}, CEBPA (CCAAT enhancer binding protein alpha) [NCBI Gene 1050] {aka C/EBP-alpha, CEBP}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, BCHE (butyrylcholinesterase) [NCBI Gene 590] {aka BCHED, CHE1, CHE2, E1}, CPT1A (carnitine palmitoyltransferase 1A) [NCBI Gene 1374] {aka CPT I, CPT1, CPT1-L, CPTI-L, L-CPT1}, IL22 (interleukin 22) [NCBI Gene 50616] {aka IL-21, IL-22, IL-D110, IL-TIF, ILTIF, TIFIL-23}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, FLII (FLII actin remodeling protein) [NCBI Gene 2314] {aka CMD2J, FLI, FLIL, Fli1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** impaired liver and kidney function (MESH:D056486), liver disorder (MESH:D017093), T2D (MESH:D003924), liver cancer (MESH:D006528), carcinogenic (MESH:D011230), lipid metabolic disorder (MESH:D052439), hypertension (MESH:D006973), weight loss (MESH:D015431), insulin resistance (MESH:D007333), cardiovascular diseases (MESH:D002318), endocrine disruption (MESH:D004700), OPs (MESH:D062025), Fatty liver (MESH:D005234), fatty infiltration (MESH:D017254), Non-alcoholic steatohepatitis (MESH:D005235), obese (MESH:D009765), hemorrhage (MESH:D006470), Damage (MESH:D020263), metabolic abnormalities (MESH:D008659), Body weight reduction (MESH:D001835), dyslipidemia (MESH:D050171), mitochondrial dysfunction (MESH:D028361), fatty (MESH:D008067), inflammation (MESH:D007249), liver complications (MESH:D008107), metabolic syndrome.e (MESH:D024821), fibrosis (MESH:D005355), liver cirrhosis (MESH:D008103), NAFLD (MESH:D065626), renal failure (MESH:D051437), cancer (MESH:D009369), gut dysbiosis (MESH:D064806), poisoning (MESH:D011041), hepatic necrosis (MESH:D047508)
- **Chemicals:** Lipid (MESH:D008055), OPP (MESH:C402885), 4-PBA (MESH:C121358), ATP (MESH:D000255), steroid hormones (MESH:D013256), glucose (MESH:D005947), paraquat (MESH:D010269), SCFAs (MESH:D005232), tris(2-butoxyethyl) phosphate (MESH:C013320), TNBP (MESH:C009524), TG (MESH:D013866), TCPP (MESH:C072782), unsaturated fatty acids (MESH:D005231), Organophosphates (MESH:D010755), 1 H (-), bile acids (MESH:D001647), Glyphosate (MESH:C010974), carbohydrate (MESH:D002241), fatty acid (MESH:D005227), malondialdehyde (MESH:D008315), monounsaturated fatty acids (MESH:D005229), 2,4-D (MESH:D015084), Chlorpyrifos (MESH:D004390), testosterone (MESH:D013739), glycogen (MESH:D006003), FFA (MESH:D005230), trichlorofon (MESH:D014236), TOCP (MESH:C025541), cholesterol (MESH:D002784), OPE (MESH:C005448), GLY (MESH:D005998), blood glucose (MESH:D001786), Methyl parathion (MESH:D008743), sugars (MESH:D000073893), TC (MESH:D013667), TPHP (MESH:C005445), esters (MESH:D004952), OCs (MESH:D006843), rapamycin (MESH:D020123), tricarboxylic acid (MESH:D014233), TCEP (MESH:C031324), Malathion (MESH:D008294), LPO (MESH:D008054), MDA (MESH:D015104)
- **Species:** Carassius carassius (crucian carp, species) [taxon 217509], gut metagenome (species) [taxon 749906], Danio rerio (leopard danio, species) [taxon 7955], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12918218/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12918218/full.md

## References

74 references — full list in the complete paper: https://tomesphere.com/paper/PMC12918218/full.md

---
Source: https://tomesphere.com/paper/PMC12918218